Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia

BACKGROUND: Once-monthly and once-every-3-months long-acting injectable (LAI) formulations of paliperidone palmitate (PP1M and PP3M, respectively) are available for the treatment of patients with schizophrenia. However, information on the comparative effectiveness and costs of using these LAIs versu...

Descripción completa

Detalles Bibliográficos
Autores principales: Basu, Anirban, Benson, Carmela, Alphs, Larry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397853/
https://www.ncbi.nlm.nih.gov/pubmed/30058979
http://dx.doi.org/10.18553/jmcp.2018.24.8.759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397853/
https://www.ncbi.nlm.nih.gov/pubmed/30058979
http://dx.doi.org/10.18553/jmcp.2018.24.8.759

Ejemplares similares